Good MorningEquity investors got a healthy dose of reality on Friday when Apple announced it was closing stores in some hard-hit stats. Economic reopenings in states like Florida and Arizona have resulted in record new COVID cases sparking the companies decision. A total of eleven stores including those in North Carolina and South Carolina are part of the closing and more could follow in the coming days.
The news from Apple highlights a growing fear, the fear that COVID will cause another round of economic shutdown in the U.S. The S&P 500 responded by reversing gains and moving lower by roughly 1.0%. The takeaways are that however dire Friday’s news may seem, the S&P 500 still closed up for the week and poised for gains in the weeks to come. An increase in the number of COVID cases won’t hold the market back so long as the economic data is improving.
Featured: 5 dividend stocks worth owning in any market condition (Ad) 
|
Markets | |
DraftKings (NASDAQ:DKNG), the world's top daily fantasy sports platform, has had little problem navigating the coronavirus pandemic. In fact, its thriving. But with American professional sports benched since early spring, how can this be?
At the onset of the COVID-19 outbreak, the stock's early 2... Read the Full Story |
|
From Our Partners | | Renewed tensions involving Iran are putting global oil supplies back in focus - and history shows certain energy stocks respond before the broader market catches on.
A new report identifies three energy stocks emerging from today's supply disruptions. One is already benefiting from the current environment; the other two may not be on your radar yet. | | See which three energy stocks made the list and why they stand out |
|
Markets | | Beating The Estimates, And The Outlook Is Good
Smith & Wesson (SWBI) just reported a blow-out quarter, literally, and has the stock positioned for longer-term gains. The company's name was recently changed from American Outdoor Brands to Smith & Wesson Brands is the same great firearms comp... Read the Full Story |
|
Markets | | Spotify (NYSE: SPOT) surged more than 14% to all-time highs as it announced two more big podcast deals. This time, the company signed exclusive deals with Warner Brothers and Kim Kardashian West. These follow Spotify’s exclusive deal for Joe Rogan a few weeks ago, which sent shares up more tha... Read the Full Story |
|
From Our Partners | | Most AI portfolios hold the same handful of chip and software names - and completely ignore the physical layer. One perception-hardware company posted ~49% Q1 revenue growth with four partnership announcements in a single month.
A free report names seven companies building the automation, robotics, and semiconductor-test infrastructure that AI requires to move beyond the data center - including an automation giant that raised full-year guidance after quarterly sales rose ~12%. | | Click here to get your free copy of this report today |
|
Markets | |
When consumers are asked the question, Coke or Pepsi, it’s a matter of taste. But tastes are starting to change? It’s no surprise that carbonated beverages are starting to fall out of favor. Consumers are becoming more mindful of what they put into their body. And that’s meant th... Read the Full Story |
|
Markets | |
Whenever a new IPO hits the market, you can typically expect a volatile first few months of trading. This was true for Peloton Interactive (NASDAQ:PTON), a company that provides a unique and interactive fitness platform. However, after Peloton’s stock price stabilized after taking a beating ... Read the Full Story |
|
From Our Partners | | Trader Graham Lindman has built a strategy around a repeating anomaly that appears in the first 60 minutes of every trading day - and it never requires holding positions overnight.
The setup has recently been refined to target up to 100% payouts by holding through the close, with 10 consecutive winning trades logged during one of the most volatile stretches since the Tariff Wars.
A new signal opportunity opens tomorrow. | | See how to join Graham Lindman's next trade before it opens |
|
Markets | |
Shares of Beyond Meat (NASDAQ:BYND) are up nearly 7% in mid-day trading. This continues a trend that has been ongoing in 2020. BYND stock has more than doubled since the beginning of the year despite seeing its share price decline by over 50% at the onset of the Covid-19 pandemic.
Why is BYND Sto... Read the Full Story |
|
Markets | | Something For The Market To Like
ESG issues, environment/social/governance, are becoming more and more important to today’s investors. Gone are the days of robber-barons, unsustainable ecological exploitation, and slave-like working conditions. In their place is a new breed of CEO, company, a... Read the Full Story |
|
Markets | | The Unseen Consequences Of COVID-19
The COVID-19 pandemic struck fast and furiously, it shut down our economy, forced us to live apart from others, and retreat into the isolated world of “home”. During this time a number of trends have emerged, trend that are already producing profits f... Read the Full Story |
|
Markets | |
Johnson & Johnson (NYSE:JNJ) stock has been volatile for the last several years, and 2020 has been no exception. But as more clarity develops surrounding the novel coronavirus, the blue-chip company is beginning to show exactly why it’s a solid investment.
Johnson & Johnson is posit... Read the Full Story |
|
Markets | |
It’s been easy to overlook eBay (NASDAQ: EBAY) over the past several years as Amazon (NASDAQ: AMZN)has taken over the e-commerce space. It has, at times, been a rocky road for Amazon’s less-glamorous competitor.
But on June 4th, eBay raised its Q2 guidance and added to the all-time hi... Read the Full Story |
|
The Early Bird Stock Of The Day Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands. | | View Today's Stock Pick |
|
